|
|
Item 5.07.
|
Submission of Matters to a Vote of Security Holders.
|
On May 21, 2026, Actuate Therapeutics, Inc. (the "Company") hosted its Annual Meeting of Stockholders ("Annual Meeting") virtually. At the Annual Meeting, the Company's stockholders (i) elected each of the two Class II director nominees listed below to the Company's Board of Directors, each to serve for a three-year term until the 2029 Annual Meeting of Stockholders, and until their respective successors are duly elected and qualified; and (ii) ratified the appointment of Crowe LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026. The final voting results regarding each proposal are set forth below.
|
|
(i)
|
The voting results with respect to the election of each director were as follows:
|
|
Nominees
|
For
|
Withheld
|
Broker Non-Votes
|
|
Aaron G.L. Fletcher, Ph.D.
|
14,877,247
|
1,883,025
|
1,871,309
|
|
Jason Keyes
|
16,727,875
|
32,397
|
1,871,309
|
|
|
(ii)
|
The voting results with respect to the ratification of the appointment of Crowe LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 were as follows:
|
|
For
|
Against
|
Abstain
|
Broker Non-Votes
|
|
18,571,817
|
50,023
|
9,741
|
-
|
